Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rein Therapeutics (RNTX) EPS (Basic) (2016 - 2025)

Rein Therapeutics filings provide 10 years of EPS (Basic) readings, the most recent being -$1.22 for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Basic) rose 44.55% year-over-year to -$1.22, compared with a TTM value of -$1.96 through Dec 2025, up 48.15%, and an annual FY2025 reading of -$1.96, up 44.16% over the prior year.
  • EPS (Basic) hit -$1.22 in Q4 2025 for Rein Therapeutics, down from -$0.21 in the prior quarter.
  • The five-year high for EPS (Basic) was -$0.06 in Q2 2021, with the low at -$5.67 in Q4 2021.
  • Median EPS (Basic) over the past 5 years was -$0.66 (2024), compared with a mean of -$1.05.
  • The sharpest move saw EPS (Basic) plummeted 4625.0% in 2021, then skyrocketed 82.36% in 2022.
  • Year by year, EPS (Basic) stood at -$5.67 in 2021, then soared by 82.36% to -$1.0 in 2022, then plummeted by 57.0% to -$1.57 in 2023, then plummeted by 40.13% to -$2.2 in 2024, then skyrocketed by 44.55% to -$1.22 in 2025.
  • According to Business Quant data, EPS (Basic) over the past three periods came in at -$1.22, -$0.21, and -$0.28 for Q4 2025, Q3 2025, and Q2 2025 respectively.